

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.



**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 211/52, A61K 31/445</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/18761 (43) International Publication Date: 7 May 1998 (07.05.98)</p>
<p>(21) International Application Number: PCT/US96/16822 (22) International Filing Date: 28 October 1996 (28.10.96) (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033 (US). (72) Inventors: REICHARD, Gregory, A.; 4 Bahama Road, Morris Plains, NJ 07950 (US). ASLANIAN, Robert, G.; 144 Philip Drive, Rockaway, NJ 07866 (US). (74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, Patent Dept. K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.</p>
<p>(54) Title: SUBSTITUTED ARYLALKYLAMINES AS NEUROKININ ANTAGONISTS</p> <p>(57) Abstract</p> <p>Compounds represented by structural formula (I) or a pharmaceutically acceptable salt thereof are disclosed, wherein: A¹ is -CH₂R⁶, -OR⁶, -N(R⁶)(R⁷), -S(O)_eR¹³, -(C(R⁶)(R⁷))₁₋₆-OR⁶, -(C(R⁶)(R⁷))₁₋₆-N(R⁶)(R⁷) or -(C(R⁶)(R⁷))₁₋₆-S(O)_eR¹³ and A² is H, or A¹ and A² together are =O, =C(R⁶)(R⁷), =NOR⁶ or =S; Q is phenyl, naphthyl, -SR⁶, -N(R⁶)(R⁷), -OR⁶ or heteroaryl; T is H, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl; b is 0, 1 or 2; b₁ is 1 or 2; X is a bond -C(O)-, -O-, -NR⁶-, -S(O)_e-, -N(R⁶)C(O)-, -C(O)N(R⁶)-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-, -C(=NOR⁶)-, -S(O)₂N(R⁶)-, -N(R⁶)S(O)₂-, -N(R⁶)C(O)O- or -OC(O)-; R⁶, R⁷, R^{8a}, and R¹³ are H, alkyl, hydroxyalkyl, alkoxy alkyl, phenyl or benzyl; or R⁶ and R⁷, together with the nitrogen to which they are attached, form a ring; R⁹ and R^{9a} independently are R⁶ or -OR⁶; Z is optionally substituted (II), wherein g is 0-3 and h is 1-4, provided the sum of h and g is 1-7; wherein the aryl, phenyl, benzyl, naphthyl, heterocycloalkyl and heteroaryl groups are optionally substituted. Methods of treating asthma, cough, bronchospasm, inflammatory diseases, and gastrointestinal disorders with said compounds, and pharmaceutical compositions comprising said compounds are disclosed.</p> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(II)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

5

10

**SUBSTITUTED ARYLALKYLAMINES AS
NEUROKININ ANTAGONISTS**

BACKGROUND OF THE INVENTION

The present invention relates to a genus of substituted
15 arylalkylamines useful as antagonists of tachykinin receptors, in particular
as antagonists of the neuropeptides neurokinin-1 receptor (NK₁) and/or
neurokinin-2 receptor (NK₂) and/or neurokinin-3 receptor (NK₃).

Neurokinin receptors are found in the nervous system and
the circulatory system and peripheral tissues of mammals, and therefore
20 are involved in a variety of biological processes. Neurokinin receptor
antagonists are consequently expected to be useful in the treatment or
prevention of various mammalian disease states, for example asthma,
cough, bronchospasm, inflammatory diseases such as arthritis, central
nervous system conditions such as migraine and epilepsy, nociception,
25 and various gastrointestinal disorders such as Crohn's disease.

In particular, NK₁ receptors have been reported to be
involved in microvascular leakage and mucus secretion, and NK₂
receptors have been associated with smooth muscle contraction, making
NK₁ and NK₂ receptor antagonists especially useful in the treatment and
30 prevention of asthma.


Some NK₁ and NK₂ receptor antagonists have previously
been disclosed: arylalkylamines were disclosed in U.S. Patent 5,350,852,
issued September 27, 1994, and spiro-substituted azacycles were
disclosed in WO 94/29309, published December 22, 1994.

35

SUMMARY OF THE INVENTION

Compounds of the present invention are represented by the
formula I

- 2 -



or a pharmaceutically acceptable salt thereof, wherein:

A¹ is -CH₂R⁶, -OR⁶, -N(R⁶)(R⁷), -S(O)_eR¹³, -(C(R⁶)(R⁷))₁₋₆-OR⁶,
 -(C(R⁶)(R⁷))₁₋₆-N(R⁶)(R⁷) or -(C(R⁶)(R⁷))₁₋₆-S(O)_eR¹³ and A² is H, or A¹
 5 and A² together are =O, =C(R⁶)(R⁷), =NOR⁶ or =S;

Q is R⁵-phenyl, R⁵-naphthyl, -SR⁶, -N(R⁶)(R⁷), -OR⁶ or
 R⁵-heteroaryl;

T is H, R⁴-aryl, R⁴-heterocycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl or
 R¹⁰-bridged cycloalkyl;

10 b is 0, 1 or 2;

b₁ is 1 or 2;

X is a bond, -C(O)-, -O-, -NR⁶-, -S(O)_e-, -N(R⁶)C(O)-, -C(O)N(R⁶)-,
 -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-, -C(=NOR⁶)-, -S(O)₂N(R⁶)-,
 -N(R⁶)S(O)₂-, -N(R⁶)C(O)O- or -OC(O)-;

15 R⁴ and R⁵ are independently 1-3 substituents independently
 selected from the group consisting of H, halogeno, -OR⁶, -OC(O)R⁶,
 -OC(O)N(R⁶)(R⁷), -N(R⁶)(R⁷), C₁₋₆ alkyl, -CF₃, -C₂F₅, -COR⁶, -CO₂R⁶,
 -CON(R⁶)(R⁷), -S(O)_eR¹³, -CN, -OCF₃, -NR⁶CO₂R¹⁶, -NR⁶COR⁷,
 -NR⁸CON(R⁶)(R⁷), R¹⁵-phenyl, R¹⁵-benzyl, NO₂, -N(R⁶)S(O)₂R¹³ or
 20 -S(O)₂N(R⁶)(R⁷); or adjacent R⁴ substituents or adjacent R⁵ substituents
 can form a -O-CH₂-O- group; and R⁴ can also be R¹⁵-heteroaryl;

R⁶, R⁷, R⁸, R^{8a}, and R¹³ are independently selected from the
 group consisting of H, C₁₋₆ alkyl, C₂-C₆ hydroxyalkyl, C₁-C₆ alkoxy-C₁-C₆
 alkyl, R¹⁵-phenyl, and R¹⁵-benzyl; or R⁶ and R⁷, together with the
 25 nitrogen to which they are attached, form a ring of 5 to 6 members,
 wherein 0, 1 or 2 ring members are selected from the group consisting of
 -O-, -S- and -N(R¹⁹)-

R⁹ and R^{9a} are independently selected from the group consisting of
 R⁶ and -OR⁶, provided that when R⁹ is OH, X is a bond, -C(O)-,
 30 -N(R⁶)C(O)- or -C(=NOR⁶)-

R¹⁰ is independently selected from the group consisting of H and
 C₁₋₆ alkyl;

R¹⁵ is 1 to 3 substituents independently selected from the group
 consisting of H, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, halogeno,

- 3 -

-CF₃, -C₂F₅, -COR¹⁰, -CO₂R¹⁰, -C(O)N(R¹⁰)₂, -S(O)_eR¹⁰, -CN,
-N(R¹⁰)COR¹⁰, -N(R¹⁰)CON(R¹⁰)₂ and -NO₂;

R¹⁶ is C₁₋₆ alkyl, R¹⁵-phenyl or R¹⁵-benzyl;


R¹⁹ is H, C₁-C₆ alkyl, -C(O)N(R¹⁰)₂, -CO₂R¹⁰, -(C(R⁸)(R⁹))_f

5 CO₂R¹⁰ or -(C(R⁸)(R⁹))_u-C(O)N(R¹⁰)₂;

f is 1-6;

u is 0-6;

Z is



10 f is 1-6;

g and j are independently 0-3;

h and k are independently 1-4, provided the sum of h and g is 1-7;

J is two hydrogen atoms, =O, =S, =NR⁹ or =NOR⁶;

L and L¹ are independently selected from the group consisting of H,

15 C₁-C₆ alkyl, C₁-C₆ alkenyl, -CH₂-cycloalkyl, R¹⁵-benzyl, R¹⁵-heteroaryl,
-C(O)R⁶, -(CH₂)_m-OR⁶, -(CH₂)_m-N(R⁶)(R⁷), -(CH₂)_m-C(O)-OR⁶ and
-(CH₂)_m-C(O)N(R⁶)(R⁷);

m is 0 to 4, provided that when j is 0, m is 1-4;

R²⁵ is H, C₁-C₆ alkyl, -CN, R¹⁵-phenyl or R¹⁵-benzyl;

20 R²⁶ and R²⁷ are independently selected from the group consisting
of H, C₁-C₆ alkyl, R⁴-aryl and R⁴-heteroaryl; or R²⁶ is H, C₁-C₆ alkyl, R⁴-
aryl or R⁴-heteroaryl, and R²⁷ is -C(O)R⁶, -C(O)-N(R⁶)(R⁷), -C(O)(R⁴-aryl),
-C(O)(R⁴-heteroaryl), -SO₂R¹³ or -SO₂-(R⁴-aryl);

R²⁸ is H, -(C(R⁶)(R¹⁹))_t-G or -(C(R⁶)(R⁷))_v-G²;

25 t and v are 0, 1, 2 or 3, provided that when j is 0, t is 1, 2 or 3;

R²⁹ is H, C₁-C₆ alkyl, -C(R¹⁰)₂S(O)_eR⁶, R⁴-phenyl or R⁴-heteroaryl;

G is H, R⁴-aryl, R⁴-hetero-cycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl,
-OR⁶, -N(R⁶)(R⁷), -COR⁶, -CO₂R⁶, -CON(R⁷)(R⁹), -S(O)_eR¹³,
-NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), -N(R⁶)S(O)₂R¹³,

30 -S(O)₂N(R⁶)(R⁷), -OC(O)R⁶, -OC(O)N(R⁶)(R⁷), -C(=NOR⁸)N(R⁶)(R⁷),
-C(=NR²⁵)N(R⁶)(R⁷), -N(R⁸)C(=NR²⁵)N(R⁶)(R⁷), -CN, -C(O)N(R⁶)OR⁷ or
-C(O)N(R⁹)-(R⁴-heteroaryl), provided that when n is 1 and u is 0, or when
R⁹ is -OR⁶, G is not -OH or -N(R⁶)(R⁷); and

G² is R⁴-aryl, R⁴-heterocycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl,

35 -COR⁶, -CO₂R¹⁶, -S(O)₂N(R⁶)(R⁷) or -CON(R⁶)(R⁷).


- 4 -

Preferred are compounds of formula I wherein X is -O-,
 -NR⁶-, -N(R⁶)C(O)-, -OC(O)NR⁶ or -N(R⁶)C(O)O. More preferred are
 compounds of formula I wherein X is -NR⁶- or -N(R⁶)C(O)-. Also preferred
 are compounds wherein b is 0 or 1 when X is -NR⁶- or -N(R⁶)C(O)-. Also
 5 preferred are compounds wherein b₁ is 1. T is preferably R⁴-aryl or R⁴-
 heteroaryl, with R⁴-aryl, especially R⁴-phenyl, being more preferred. Also
 preferred are compounds wherein R^{8a} and R^{9a} are independently
 hydrogen, hydroxyalkyl or alkoxyalkyl, with hydrogen being more
 preferred. Especially preferred are compounds wherein R^{8a} and R^{9a} are
 10 each hydrogen, X is -NR⁶- or -N(R⁶)C(O)-, T is R⁴-aryl and R⁴ is two
 substituents selected from C₁-C₆ alkyl, halogeno, -CF₃ and C₁-C₆ alkoxy.
 When T is R⁴-heteroaryl, a preferred definition includes R⁴-pyridinyl.


Also preferred are compounds wherein Q is R⁵-phenyl, R⁵-
 naphthyl or R⁵-heteroaryl; especially preferred definitions for Q are R⁵-
 15 phenyl, wherein R⁵ is preferably two halogeno substituents, and
 benzothienyl.

Preferred are compounds of formula I wherein A¹ is -OR⁶,
 -N(R⁶)(R⁷), -S(O)_eR¹³ or -(C(R⁶)(R⁷))₁₋₆-N(R⁶)(R⁷) and A² is H; also
 preferred compounds are where A¹ and A² together are =O, =C(R⁶)(R⁷) or
 20 =NOR⁶.

Preferred definitions of Z are




with the following groups being more preferred:



25

More preferred are the following Z groups:

- 5 -



This invention also relates to the use of a compound of formula I in the treatment of asthma, cough, bronchospasm, inflammatory diseases such as arthritis, central nervous system conditions such as migraine and epilepsy, nociception, and various gastrointestinal disorders such as Crohn's disease.

In another aspect, the invention relates to a pharmaceutical composition comprising a compound of formula I in a pharmaceutically acceptable carrier. The invention also relates to the use of said pharmaceutical composition in the treatment of asthma, cough, bronchospasm, inflammatory diseases such as arthritis, migraine, nociception, and various gastrointestinal disorders such as Crohn's disease.

DETAILED DESCRIPTION

As used herein, the term "alkyl" means straight or branched alkyl chains. "Lower alkyl" refers to alkyl chains of 1-6 carbon atoms and, similarly, lower alkoxy refers to alkoxy chains of 1-6 carbon atoms.

"Aryl" means phenyl, naphthyl, indenyl, tetrahydronaphthyl, indanyl, anthracenyl or fluorenyl.

"Halogeno" refers to fluoro, chloro, bromo or iodo atoms.

"Heterocycloalkyl" refers to tetrahydrofuranyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and piperazinyl. R⁴-heterocycloalkyl refers to such groups wherein substitutable ring carbon atoms have an R⁴ substituent.

"Heteroaryl" refers to 5- to 10-membered single or benzofused aromatic rings comprising 1 to 4 heteroatoms independently selected from the group consisting of -O-, -S- and -N=, provided that the rings do not include adjacent oxygen and/or sulfur atoms. Examples of single-ring heteroaryl groups are pyridyl, oxazolyl, isoxazolyl, oxadiazolyl, furanyl, pyrrolyl, thienyl, imidazolyl, pyrazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrazinyl, pyrimidyl, pyridazinyl and triazolyl. Examples of benzofused heteroaryl groups are indolyl, quinolyl,

- 6 -

benzothienyl (i.e., thianaphthenyl), benzimidazolyl, benzofuranyl, benzoxazolyl and benzofurazanyl. N-oxides of nitrogen-containing heteroaryl groups are also included. All positional isomers are contemplated, e.g., 1-pyridyl, 2-pyridyl, 3-pyridyl and 4-pyridyl. R⁴-
5 heteroaryl refers to such groups wherein substitutable ring carbon atoms have an R⁴ substituent.

Where R⁶ and R⁷ substituents form a ring and additional heteroatoms are present, the rings do not include adjacent oxygen and/or sulfur atoms or three adjacent heteroatoms. Typical rings so formed are
10 morpholinyl, piperazinyl and piperidinyl.

In the above definitions, wherein variables such as R⁶, R⁷, R⁸, R⁹, R¹³ and R¹⁵ are said to be independently selected from a group of substituents, we mean that R⁶, R⁷, R⁸, R⁹, R¹³ and R¹⁵ are independently selected, but also that where an R⁶, R⁷, R⁸, R⁹, R¹³ or R¹⁵ variable occurs
15 more than once in a molecule, those occurrences are independently selected (e.g., if R⁴ is -OR⁶ wherein R⁶ is methyl, X can be -N(R⁶)- wherein R⁶ is ethyl). Similarly, R⁴ and R⁵ can be independently selected from a group of substituents, and where more than one R⁴ and R⁵ are present, the substituents are independently selected; those skilled in the art will
20 recognize that the size and nature of the substituent(s) will affect the number of substituents which can be present.

Compounds of the invention can have at least one asymmetrical carbon atom and therefore all isomers, including diastereomers, enantiomers and rotational isomers are contemplated as
25 being part of this invention. The invention includes d and l isomers in both pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of a compound of formula I.

30 Those skilled in the art will appreciate that for some compounds of formula I, one isomer will show greater pharmacological activity than other isomers.

Compounds of the invention have at least one amino group which can form pharmaceutically acceptable salts with organic and
35 inorganic acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other

- 7 -


mineral and carboxylic acids well known to those in the art. The salt is prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt. The free base form may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous sodium bicarbonate. The free base form differs from its respective salt form somewhat in certain physical properties, such as solubility in polar solvents, but the salt is otherwise equivalent to its respective free base forms for purposes of the invention.

Certain compounds of the invention are acidic (e.g., those compounds which possess a carboxyl group). These compounds form pharmaceutically acceptable salts with inorganic and organic bases. Examples of such salts are the sodium, potassium, calcium, aluminum, gold and silver salts. Also included are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.

Compounds of formula I can be prepared using methods well known to those skilled in the art. Following are typical procedures for preparing various compounds; the skilled artisan will recognize that other procedures may be applicable, and that the procedures may be suitable modified to prepare other compounds within the scope of formula I.

Procedure A:


Compounds of formula I wherein X is $-\text{C}(\text{O})-$, $-\text{O}-$, $-\text{S}(\text{O})_2-$, $-\text{C}(\text{O})\text{N}(\text{R}^6)-$, $-\text{OC}(\text{O})\text{NR}^6-$, $-\text{OC}(=\text{S})\text{NR}^6-$, $-\text{C}(=\text{NOR}^6)-$, $-\text{S}(\text{O})_2\text{N}(\text{R}^6)-$ or $-\text{OC}(\text{O})-$, Q is R^5 phenyl, b_1 is 1 or 2, and the remaining variables are as defined above, can be prepared as shown in the following reaction scheme:



In step 1, compound 1, wherein R^5 is as defined above, is treated with a halogenating agent such as I_2 or N-bromosuccinimide in an organic solvent such as CH_3CN , THF or DMF at a temperature in the range of 0 to 25°C to give the halolactone 2.

- 8 -


Step 2:



In step 2, compound 2 is dissolved in an alcohol R^{10}OH wherein R^{10} is preferably methyl. A base such as Cs_2CO_3 or Na_2CO_3 is added and the mixture stirred at a temperature range of 0 to 50°C to give the epoxide 3.


- 5 Alternatively, a lower alkyl ester of 1 can be epoxidized by a suitable epoxidizing agent such as dimethyl dioxirane or m-CPBA to obtain a compound of formula 3.

Step 3:



- 10 In step 3, a solution of epoxide 3 in an alcohol such as CH_3OH , $\text{CH}_3\text{CH}_2\text{OH}$, or more preferably $\text{CF}_3\text{CH}_2\text{OH}$, is treated with a secondary amine Z nucleophile where R^4 is as defined above, at 0 to 90°C to give the lactone 4.

Step 4:




- 15 For compounds where X is $-\text{C}(\text{O})\text{N}(\text{R}^6)-$ and b_1 is 1, lactone 4 is treated with the corresponding dialkylamine $-\text{N}(\text{R}^6)\text{C}(\text{R}^{9a})(\text{R}^{8a})-\text{T}$ in an alcohol such as CH_3OH , $\text{CH}_3\text{CH}_2\text{OH}$, or more preferably $\text{CF}_3\text{CH}_2\text{OH}$, at 0 to 90°C to give the amide 5. Compounds of formula 5 can be converted to the corresponding keto compounds (wherein A^1 and A^2 together are $=\text{O}$) by oxidation with a suitable reagent such as pyridinium dichromate, Dess
- 20 Martin reagent, Jones reagent, TPAP, or Swern oxidation; the keto compounds are converted to the corresponding oximes (compounds wherein A^1 and A^2 together are $=\text{NOR}^6$) by treatment of the keto compound with hydroxyl amine or an appropriate alkoxyl amine in pyridine at 23°C to 80°C . Accordingly, the corresponding olefins
- 25 (compounds wherein A^1 and A^2 together are $=\text{C}(\text{R}^6)(\text{R}^7)$) can be prepared

- 9 -

from the respective keto compounds by using standard Wittig chemistry known to those skilled in the art.

Step 4a:




- For compounds where X is -C(O)-, -O-, -S(O)_e-, -OC(O)NR⁶-,
 5 -OC(=S)NR⁶-, -C(=NOR⁶)-, -S(O)₂N(R⁶)- or -OC(O)- and b₁ is 2, lactone 4 is treated with an appropriate reducing agent such as Dibal-H, LAH, LiBH₄ or NaBH₄, with a temperature in the range of -78°C to 80°C to give the corresponding diol 4b. With appropriate protection of reactive groups, compounds of formula 4b can be converted to compounds where X is
 10 -C(O)-, -O-, -S(O)_e-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -C(=NOR⁶)-, -S(O)₂N(R⁶)- or -OC(O)- by appropriate functional group interchange or functionalization of the terminal alcohol group. The corresponding keto compounds (compounds wherein A¹ and A² together are =O) may be prepared by oxidation with a suitable reagent such as pyridinium
 15 dichromate, Dess Martin reagent, Jones reagent, TPAP or Swern oxidation; synthesis of the corresponding oximes (compounds wherein A¹ and A² together are =NOR⁶) are made by treatment of the keto compound with hydroxyl amine or an appropriate alkoxy amine in pyridine at 23°C to 80 °C. Accordingly, the corresponding olefins (compounds wherein A¹
 20 and A² together are =C(R⁶)(R⁷)) can be prepared from the respective keto compounds by using standard Wittig chemistry known to those skilled in the art.

Procedure B:

- Compounds of formula I wherein X is -NR⁶-, -NR⁶C(O)-,
 25 -N(R⁶)C(=S)O-, -N(R⁶)S(O)₂-, -N(R⁶)C(O)O- or -N(R⁶)C(O)N(R⁷)-, Q is R⁵ phenyl, b₁ is 1 and the remaining variables are as defined above, can be prepared as shown in the following reaction scheme:

Step 1:




- In step 1, the acid 1 is subjected to conditions typical of a Curtius
 30 rearrangement, for example; treatment with diphenylphosphoryl azide and

- 10 -

a suitable base such as triethyl amine (Et_3N) in an appropriate solvent such as *t*-butanol. After heating to reflux, cooling and appropriate purification such as recrystallization or silica gel chromatography, the corresponding N-Boc protected amine of compound 6 is isolated.


- 5 Deprotection of the Boc group by standard conditions known to those skilled in the art, such as treatment with an acid such as hydrochloric acid or trifluoroacetic acid, provides compound 6.

Step 2:



- In step 2, amine 6 is acylated by standard procedures, for example by treatment with an acid chloride of the formula $\text{T-C(R}^{9a})(\text{R}^{8a})\text{COCl}$, wherein T, R^{8a} and R^{9a} are as defined as above, in the presence of an amine base in an inert organic solvent such as CH_2Cl_2 or toluene, preferably CH_2Cl_2 , at a temperature of from -10 to 50°C . Suitable bases include $(\text{CH}_3)_3\text{N}$, Et_3N and pyridine, preferably Et_3N . Other acylating agents such as anhydrides are also suitable. Other coupling methods known to those skilled in the art, such as EDC coupling, may also be employed.
- Correspondingly, for the preparation of compounds wherein X is $-\text{N(R}^6)\text{S(O)}_2-$, $-\text{N(R}^6)\text{C(O)O}-$ or $-\text{N(R}^6)\text{C(O)N(R}^7)-$, the amine is treated with the appropriate sulfonyl halide, chloroformate, or isocyanate respectively.

Step 3:




20

- In step 3, compound Z is treated with a base such as NaH or LDA, in an inert organic solvent such as THF, ether, DMSO or DMF, preferably THF. The resulting anion is treated with an alkylating agent R^6L , wherein R^6 is as defined above and L is a suitable leaving group such as Cl, Br, I, triflate or mesylate, to give the product of formula 8. The reactions are typically run at 0 to 50°C .


25

Step 4:



In step 3, compound 8 is oxidized to the epoxide 9 by treatment with an oxidizing agent such as dimethyl dioxirane in an inert organic solvent such as acetone at a temperature of 0 to 30°C. Other suitable oxidants can be used, for example m-CPBA in a solvent such as CH₂Cl₂. Suitable protective groups on R^{9a}, R^{8a}, and T on moieties susceptible to oxidation under these conditions may be necessary.


Step 5:



In step 5, the epoxide of formula 9 is converted to the amine of formula 11 by treating a solution of epoxide 9 in an alcohol such as CH₃OH, CH₃CH₂OH, or more preferably CF₃CH₂OH, with a secondary amine Z nucleophile, 10 as defined above, at 0 to 90°C to give the amino alcohol of formula 11. Compounds of formula 11 can be converted to the corresponding keto (compounds wherein A¹ and A² together are =O) then to the corresponding oximes (compounds wherein A¹ and A² together are =NOR⁶) as described above in Procedure A. Accordingly, the corresponding olefins (compounds wherein A¹ and A² together are =C(R⁶)(R⁷)) may be prepared from the keto compounds using standard Wittig chemistry known to those skilled in the art.

Procedure C:

Step 1:



20

For compounds where X is a bond, -C(O)-, -O-, -NR⁶-, -S(O)_e-, -N(R⁶)C(O)-, -C(O)N(R⁶)-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-, -C(=NOR⁶)-, -S(O)₂N(R⁶)-, -N(R⁶)S(O)₂-, -N(R⁶)C(O)O- or -OC(O)- and b₁ is 1, the nitro olefin 12 is added to a mixture of a copper salt, preferably CuCN, and vinyl magnesium bromide in a suitable solvent, preferably THF, with a temperature range of -78 °C to 0 °C, to give after workup and appropriate purification the nitro product 13. This product can be reduced to give the primary amine 6 or the nitro group may be transformed to the corresponding carboxylic acid via a standard Nef reaction, then to the

- 12 -

primary alcohol with functional group transformations known to those skilled in the art. Such compounds can be converted to compounds where X is -C(O)-, -O-, -S(O)₂-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -C(=NOR⁶)-, -S(O)₂N(R⁶)- or -OC(O)- by appropriate functional group interchange or


5 functionalization of the terminal alcohol group. The corresponding keto compounds (i.e., compounds wherein A¹ and A² together are =O) may be prepared by oxidation with a suitable reagents such as pyridinium dichromate, Dess Martin reagent, Jones reagent, TPAP, or Swern oxidation; synthesis of the corresponding oximes (i.e., compounds

10 wherein A¹ and A² together are =NOR⁶) are made by treatment of the keto compound with hydroxyl amine or an appropriate alkoxyl amine in pyridine at 23°C to 80 °C. Accordingly, the corresponding olefins (compounds wherein A¹ and A² together are =C(R⁶)(R⁷)) can be prepared from the respective keto compounds by using standard Wittig chemistry

15 known to those skilled in the art.

Reactive groups not involved in the above processes can be protected during the reactions with conventional protecting groups which can be removed by standard procedures after the reaction. The following Table 1 shows some typical protecting groups:

20

Group to be Protected	Group to be Protected and Protecting Group
-COOH	-COOalkyl, -COObenzyl, -COOphenyl
>NH	>NCOalkyl, >NCObenzyl, >NCOphenyl, \NCH ₂ OCH ₂ CH ₂ Si(CH ₃) ₃ , \NC(O)OC(CH ₃) ₃ , \N-benzyl, \NSi(CH ₃) ₃ , \NSi(CH ₃) ₂ C(CH ₃) ₃
-NH ₂	
-OH	-OCH ₃ , -OCH ₂ OCH ₃ , -OSi(CH ₃) ₃ , -OSi(CH ₃) ₂ C(CH ₃) ₃ , or -OCH ₂ phenyl

- 13 -

Compounds of formula I have been found to be antagonists of NK₁ and/or NK₂ and/or NK₃ receptors, and are therefore useful in treating conditions caused or aggravated by the activity of said receptors.


The present invention also relates to a pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier. Compounds of this invention can be administered in conventional oral dosage forms such as capsules, tablets, powders, cachets, suspensions or solutions, or in injectable dosage forms such as solutions, suspensions, or powders for reconstitution. The pharmaceutical compositions can be prepared with conventional excipients and additives, using well known pharmaceutical formulation techniques. Pharmaceutically acceptable excipients and additives include non-toxic and chemically compatible fillers, binders, disintegrants, buffers, preservatives, anti-oxidants, lubricants, flavorings, thickeners, coloring agents, emulsifiers and the like.

The daily dose of a compound of formula I for treating asthma, cough, bronchospasm, inflammatory diseases, migraine, nociception and gastrointestinal disorders is about 0.1 mg to about 20 mg/kg of body weight per day, preferably about 0.5 to about 15 mg/kg. For an average body weight of 70 kg, the dosage range is therefore from about 1 to about 1500 mg of drug per day, preferably about 50 to about 200 mg, more preferably about 50 to about 500 mg/kg per day, given in a single dose or 2-4 divided doses. The exact dose, however, is determined by the attending clinician and is dependent on the potency of the compound administered, the age, weight, condition and response of the patient.

Following are examples of preparing starting materials and compounds of formula I.

Example 1

N-[2-(3,4-dichlorophenyl)-3-hydroxy-4-(4-hydroxy-4-phenyl-1-piperidiny)butyl]-N-methyl benzamide



- 14 -

Step 1: Cool a solution of 3-(3,4-dichlorophenyl)-2-propenoic acid (100 g, 461 mmol) in dry DMF (500 mL) to 0°C and treat with Cs₂CO₃ (100 g, 307 mmol, 0.66 eq). Stir the resulting off-white slurry for 15 min, then add CH₃I (33 mL, 530 mmol, 1.15 eq) via syringe. After 1 h, add
5 additional DMF (250 mL), stir the slurry for 14 h and partition between EtOAc (1.5 L) and half saturated aqueous NaHCO₃ (500 mL). Separate the organic layer and extract the aqueous layer twice with EtOAc (1 L, 500 mL). Wash the combined organic layers with half saturated aqueous NaHCO₃ (500 mL) and water (5 x 500 mL), then dry (Na₂SO₄) and
10 concentrate to obtain 105.4 g (456 mmol, 99%) of methyl 3-(3,4-dichlorophenyl)-2-propenoate as light brown needles.

Step 2: Treat a solution of the product of Step 1 (15 g, 65 mmol) in dry THF (250 mL), kept cool in a large ambient temperature water bath, with Dibal-H (140 mL, 140 mmol, 2.15 eq) over 30 min. Stir the resulting
15 solution for 30 min at 23 °C, pour into Et₂O (500 mL), treat with water (5 mL), 15 % NaOH (5 mL) and water (15 mL). Stir for 5 min, dilute the mixture with Et₂O (200 mL) and treat with 15 % NaOH (15 mL). Add MgSO₄ to cause a colorless precipitate. Remove the aluminum salts by filtration through a coarse glass frit. Wash the solids with Et₂O (1 L) and
20 concentrate the filtrate *in vacuo* to give 13.2 g (65 mmol, 99%) of 3-(3,4-dichlorophenyl)-2-propene-1-ol as an off-white solid.

Step 3: Treat a solution of the product of step 2 (13.2 g, 65 mmol) in CH₂Cl₂ (250 mL) at 0 °C with pyridine (7.89 mL, 97.5 mmol, 1.5 eq) and dimethylaminopyridine (397 mg, 3.25 0.05 eq), followed by CH₃COCl
25 (6.48 mL, 74.75 mmol, 1.15 eq). Allow the mixture to warm to 23 °C, pour into 1 M HCl (100 mL) and wash the resulting organic layer again with 1 M HCl (100 mL), followed by water (5 x 100 mL; pH=6.5-7). Dry the organic layer (Na₂SO₄) and concentrate to obtain 15.4 g (62.9 mmol, 97%) of 3-(3,4-dichlorophenyl)-2-propene-1-ol acetate as a colorless oil.

Step 4: Treat a solution of the product of step 3 (15 g, 61 mmol, dried by azeotropic distillation with toluene, 1 x 50 mL) in dry THF (250 mL) at -78°C with chlorotriethylsilane (20.2 mL, 120 mmol, 2.0 eq) rapidly followed by the addition of potassium bis(trimethylsilyl)amide (183 mL, 91.5 mmol, 1.5 eq of 0.5 M in toluene) via addition funnel over 50 min.
35 Allow the mixture to warm to 23°C and heat to reflux for 3 h. Gradually cool the solution overnight, then quench with saturated NH₄Cl (150 mL). Stir the resultant mixture vigorously for 3h, treat with 1M HCl (150 mL) and

- 15 -

then extract with Et₂O (500 mL). Extract the aqueous layer with Et₂O (400 mL), wash the combined organic layers with 5% NaOH (300 mL) and extract with 5 % NaOH (8 x 150 mL). Cool the combined aqueous layers to 5°C and, maintaining the temperature at 5-10 °C, carefully acidify with concentrated HCl (ca 175 mL) to pH 1. Extract the aqueous layer with CH₂Cl₂ (2 x 800 mL), dry (Na₂SO₄) and concentrate to give 13.4 g (54.5 mmol, 89%) of 3-(3,4-dichlorophenyl)-4-pentenoic acid as a faint yellow oil.

Step 5: Treat a solution of the product of step 4 (13.75 g, 56 mmol, dried by azeotropic distillation with toluene, 100 mL) in dry, freshly distilled *t*-butanol (250 mL) with freshly distilled Et₃N (9.34 mL, 70 mmol, 1.25 eq) followed by diphenylphosphoryl azide (15.1 mL, 70 mmol, 1.25 eq). Heat the resulting solution to reflux for 24 h, cool and concentrate *in vacuo*. Treat the resultant product with toluene (100 mL), concentrate (2 x), dissolve in hexane:EtOAc (1:1) and filter through a pad of silica gel (4 x 10 cm), eluting with hexane:EtOAc (1:1) (1 L). Concentrate the filtrate to obtain 20.7 g of crude 1,1-dimethylethyl-[2-(3,4-dichlorophenyl)-3-butenyl] carbamate.

Step 6: Treat a solution of the product of step 5 (5.32 g of ca 88% pure, 14.8 mmol) in CH₂Cl₂ (100 mL) with trifluoroacetic acid (10 mL) and stir for 2 h at 23°C. Treat the mixture with heptane (50 mL) and concentrate *in vacuo*. Take up the resulting crude product in hexane:EtOAc (1:1) and apply to a pad of silica gel (4 x 10 cm) packed with hexane:EtOAc (1:1). Wash the plug with the same solvent (1 L) and then elute the desired product with CH₂Cl₂:CH₃OH (saturated with ammonia) (9:1) (1.5 L). Combine the product washes and concentrate to give 3.9 g crude amine used in the next step without further purification.

Step 7: Cool a solution of the product of step 6 (14.8 mmol) in CH₂Cl₂ (100 mL) to 0°C and treat with Et₃N (3.5 mL, 25.2 mmol, 1.5 eq) and benzoyl chloride (2.1 mL, 17.6 mmol, 1.05 eq). After 10 min, dilute the mixture to 150 mL with CH₂Cl₂ and wash with 10 % aqueous citric acid (50 mL), water (50 mL) and aqueous saturated NaHCO₃ (50 mL), then dry (Na₂SO₄) and concentrate. Triturate the resulting crude off-white solid with hexane (40 mL) to give 3.29 g (10 mmol, 68%, over three steps) of *N*-[2-(3,4-dichlorophenyl)-3-butenyl] benzamide as a colorless solid.

Step 8: Wash a suspension of NaH (312 mg of 60% in mineral oil, 7.81 mmol, 1.25 eq) in hexane with dry pentane (2 x 100 mL), suspend in

- 16 -


dry THF (30 mL) and treat with the product of step 7 (2.0g, 6.25 mmol) at 23°C. Stir the resulting yellow suspension for 20 min at 23°C, then add CH₃I (777 µL, 12.5 mmol, 2.0 eq). After 1 h, pour the mixture onto a pad of silica gel packed with hexane:EtOAc (1:1) (500 mL) and concentrate the filtrate to give 2.1 g (6.25 mmol, >99%) of *N*-[2-(3,4-dichlorophenyl)-3-

Step 9: Treat a solution of the product of step 8 (2.1 g, 6.25 mmol) in dry CH₂Cl₂ (50 mL) with a freshly prepared solution of dimethyldioxirane in acetone (100 mL of ca 0.08 M in acetone). Stir the solution for 20 h, concentrate *in vacuo*, azeotrope with toluene (2 x 75 mL) and then purify by silica gel chromatography (column: 4 x 16 cm; eluant: hexane:EtOAc (1:1), to obtain isomer A: 854 mg (2.44 mmol, 39%) of (*trans*)-*N*-[2-(3,4-dichlorophenyl)-2-oxiranylethyl]-*N*-methyl benzamide as a colorless oil; and isomer B: 1.04 g (2.98 mmol, 48%) of (*cis*)-*N*-[2-(3,4-dichlorophenyl)-2-oxiranylethyl]-*N*-methyl benzamide as a colorless solid (total yield 87%).

Step 10: Treat a solution of isomer A of step 9 (201 mg, 0.574 mmol) in 2,2,2 trifluoroethanol (3 ml) with 4-hydroxy-4-phenyl piperidine (508 mg, 2.87 mmol, 5 eq). Stir the resulting light yellow solution for 24 h at 23°C, concentrate *in vacuo*, azeotrope with toluene (2 x 5 ml) and concentrate. Purify the resulting crude solid by silica gel chromatography (column: 2.5 x 18 cm; eluant: gradient CH₂Cl₂:CH₃OH (saturated with ammonia) (97:3) to (95:5)) to obtain 302.8 mg (0.574 mmol, >99% of the title compound as a colorless foam. HRMS (FAB, M+H⁺): *m/e* calc'd for [C₂₉H₃₃Cl₂N₂O₃]⁺: 527.1868, found 527.1853.


The compounds of Examples 2-4 are prepared by methods similar to those described in Example 1. For Examples 3-4, the starting material is 3-(4-methoxyphenyl)-4-pentenoic acid, prepared from octyl-3-(4-methoxy)-2-propenopate in a manner similar to the procedure described in Example 1, steps 2-4.

Example 2




HRMS (FAB, M+H⁺): *m/e* calc'd for [C₂₉H₃₃Cl₂N₂O₃]⁺: 527.1868, found 527.1863. (Stereochemistry shown is relative.)

- 17 -

Example 3


HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₀H₃₆N₂O₄]⁺: 489.2753, found 489.2754.

5

Example 4

HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₀H₃₆N₂O₄]⁺: 489.2753, found 489.2735.

10

Example 5

- Step 1:** Cool a suspension of CuCN (3.3 g, 36.6 mmol, 1.1 eq) in dry THF under argon to -78°C and treat with vinyl magnesium bromide (73.8 mL of 1M solution in THF, 78 mmol, 2.2eq) dropwise over a period of 30 min. Warm the mixture to 0°C. After stirring for 10 min at 0°C, cool the solution to -20°C, stir for 10 min, then add a solution of *trans*-β-nitrostyrene (5 g, 33.5 mmol) in dry THF (15 mL). Stir the suspension for 1 h, then pour into a 1:2 mixture of 0.1 M HCl / acetic acid (600 mL). Extract the resulting aqueous phase with CH₂Cl₂ (400 mL), wash the organic layers with water (2 x 300 mL), dry (Na₂SO₄) and concentrate to give 7 g of crude product. Purify by silical gel chromatography (7 x 16 cm, eluant: hexane/CH₂Cl₂

- 18 -


(3:1) (1L) gradient to (2:1)) to obtain 2.5 g (14.1 mmol, 42%) of the desired product as a light yellow liquid.

Step 2: Shake aluminum strips (5 g) with a solution of 2% aqueous HgCl₂ (60 mL) for 1.5 min. Decant the aqueous layer, wash the foil with ethanol (2 x 50 mL) followed by ether (2 x 50 mL), and suspend in ether (50 mL)/THF (30 mL). Add the product of step 1 (2.5 g) as a solution in THF (20 mL). Add water (5 mL) and CH₃OH (5 mL) and stir the suspension for 48 h at 23°C. Filter the resulting suspension through a cake of celite (10 x 3.5 cm), rinsing with CH₃OH. Concentrate the filtrate to obtain 2.1 g (14.1 mol, >95 %) of 2-(3,4-dichlorophenyl)-3-butenyl amine as a light yellow oil.

Step3: Use the product of step 2 in a procedure similar to that described in Example 1, steps 7-10, to obtain the title compound (cis isomer):

15 HRMS (FAB, M+H⁺): *m/e* calc'd for [C₂₉H₃₅N₂O₃]⁺: 459.2648, found 459.2643.

Example 6




Isolate the trans isomer prepared by the process described in

20 Example 5: HRMS (FAB, M+H⁺): *m/e* calc'd for [C₂₉H₃₅N₂O₃]⁺: 459.2648, found 459.2644.

Examples 7 and 8 (diastereomers) are prepared in a similar manner to that described in Example 5 using 4-chloro-*trans*- β -nitrostyrene as the starting material.


25

Example 7




HRMS (FAB, M+H⁺): *m/e* calc'd for [C₂₉H₃₃Cl₂N₂O₃]⁺: 493.2258, found 493.2261.

- 19 -


Example 8

HRMS (FAB, M+H⁺): *m/e* calc'd for [C₂₉H₃₃ClN₂O₃]⁺: 493.2258, found 493.2270.

- 5 Examples 9 and 10 were prepared by a procedure similar to that of Example 5 using 4-methyl-*trans*-β-nitrostyrene as the starting material.


Example 9

- 10 HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₀H₃₆N₂O₃]⁺: 473.2804, found 473.2803.

Example 10

HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₀H₃₆N₂O₃]⁺: 473.2804, found 473.2798.


15

Example 11

Using 1,1-dimethylethyl-[2-(3,4-dichlorophenyl)-3-butenyl] carbamate as the starting material, carry out the process described in Example 1, steps 9-10, to obtain the title compound.


- 20 -

HRMS (FAB, M+H⁺): *m/e* calc'd for [C₂₆H₃₄Cl₂N₂O₄]⁺: 509.1974, found 509.1968.

Example 12


5 Treat the product of Example 11 in a manner similar to that described in Example 1, step 8 to obtain the title compound.
HRMS (FAB, M+H⁺): *m/e* calc'd for [C₂₇H₃₆Cl₂N₂O₄]⁺: 523.2130, found 523.2136.

10 Examples 13, 14 and 15 are prepared from Examples 1, 2 and 2, respectively, using a procedure similar to that of Example 1, step 8.

Example 13


HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₀H₃₄Cl₂N₂O₃]⁺: 541.2025, found 541.2040.

15

Example 14


HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₀H₃₄Cl₂N₂O₃]⁺: 541.2025, found 541.2037.

- 21 -

Example 15

HRMS (FAB, $M+H^+$): m/e calc'd for $[C_{31}H_{36}Cl_2N_2O_3]^+$: 555.2181, found 555.2181.


5

Example 16

Treat the product of Example 1 in acetone with Jones reagent and stir at 0°C for 1 h. Extract the product with CH_2Cl_2 and purify by silica gel chromatography to obtain the title compound. MS : m/e 525 (FAB, $M+H^+$).


10

Examples 17 and 18, regioisomers of the oxime ether, are prepared by heating the product of Example 16 in pyridine with *O*-methoxylamine HCl at 60°C for 30 min. After removing the pyridine in vacuo, the crude product is purified on a silica gel column.

Example 17

15


HRMS (FAB, $M+H^+$): m/e calc'd for $[C_{30}H_{33}Cl_2N_3O_3]^+$: 554.1977, found 554.1985.

Example 18


- 22 -

HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₀H₃₃Cl₂N₃O₃]⁺: 554.1977, found 554.1979.

Examples 19, 20, 21 and 22 are prepared from Examples 1, 2, 5 and 6, respectively, using a procedure similar to that described in Example 1, step 8, but using 3,5-(bistrifluoromethyl)benzyl bromide as the alkylhalide.


Example 19

HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₈H₃₇Cl₂F₆N₂O₃]⁺: 753.2085, found 753.2058.

Example 20


HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₈H₃₇Cl₂F₆N₂O₃]⁺: 753.2085, found 753.2065.

15

Example 21


HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₈H₃₉F₆N₂O₃]⁺: 685.2865, found 685.2851

- 23 -

Exempl 22


HRMS (FAB, $M+H^+$): m/e calc'd for $[C_{38}H_{39}F_6N_2O_3]^+$: 685.2865, found 685.2864.

- 5 Examples 23 and 24 are prepared from Examples 1 and 2, respectively, by stirring the amide in dry THF with $LiAlH_4$ for 30 min. at $23^\circ C$, partitioning between Et_2O , water and NaOH, removing the aluminum salts by filtration, and filtering through a plug of silica gel.

Example 23

10

HRMS (FAB, $M+H^+$): m/e calc'd for $[C_{29}H_{35}Cl_2N_2O_2]^+$: 513.2076, found 513.2069.


Example 24

- 15 HRMS (FAB, $M+H^+$): m/e calc'd for $[C_{29}H_{35}Cl_2N_2O_2]^+$: 513.2076, found 513.2058.

 Examples 25 and 26 were prepared from Examples 19 and 20, respectively, using a procedure similar to that used for Examples 23 and 24, using borane-dimethyl sulfide as the reductant.


20

- 24 -

Example 25

HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₈H₃₉Cl₂F₆N₂O₂]⁺: 739.2293, found 739.2289.

5

Example 26

HRMS (FAB, M+H⁺): *m/e* calc'd for [C₃₈H₃₉Cl₂F₆N₂O₂]⁺: 739.2293, found 739.2280.

10 The following formulations exemplify some of the dosage forms of this invention. In each, the term "active compound" refers to a compound of formula I.

EXAMPLE A**Tablets**

<u>No.</u>	<u>Ingredient</u>	<u>mg/tablet</u>	<u>mg/tablet</u>
1	Active Compound	100	500
2	Lactose USP	122	113
3	Corn Starch, Food Grade, as a 10% paste in Purified Water	30	40
4	Corn Starch, Food Grade	45	40
5	Magnesium Stearate	<u>3</u>	<u>7</u>
	Total	300	700

15 **Method of Manufacture**

Mix Item Nos. 1 and 2 in suitable mixer for 10-15 minutes.
Granulate the mixture with Item No. 3. Mill the damp granules through a

- 25 -

coarse screen (e.g., 1/4", 0.63 cm) if necessary. Dry the damp granules. Screen the dried granules if necessary and mix with Item No. 4 and mix for 10-15 minutes. Add Item No. 5 and mix for 1-3 minutes. Compress the mixture to appropriate size and weight on a suitable tablet machine.

5

EXAMPLE BCapsules

<u>No.</u>	<u>Ingredient</u>	<u>mg/tablet</u>	<u>mg/tablet</u>
1	Active Compound	100	500
2	Lactose USP	106	123
3	Corn Starch, Food Grade	40	70
4	Magnesium Stearate NF	<u>4</u>	<u>7</u>
	Total	250	700

Method of Manufacture

Mix Item Nos. 1, 2 and 3 in a suitable blender for 10-15 minutes. Add Item No. 4 and mix for 1-3 minutes. Fill the mixture into suitable two-piece hard gelatin capsules on a suitable encapsulating machine.

10

EXAMPLE CSterile Powder for Injection

<u>Ingredient</u>	<u>mg/vial</u>	<u>mg/vial</u>
Active sterile powder	100	500

For reconstitution add sterile water for injection or bacteriostatic water for injection.

15

The *in vitro* and *in vivo* activity of the compounds of formula I can be determined by the following procedures.

In vitro procedure to identify NK₁ activity

20

Test compounds are evaluated for their ability to inhibit the activity of the NK₁ agonist Substance P on the isolated guinea pig vas deferens. Freshly cut vas deferens are removed from male Hartley guinea pigs (230-350g) and suspended in 25 ml tissue baths containing Krebs-Henseleit solution warmed to 37°C and constantly aerated with 95% O₂ and 5% CO₂. Tissues are adjusted to 0.5 g and allowed to equilibrate for a period of 30 minutes. The vas deferens are exposed to an electrical field stimulation (Grass S48 Stimulator) every 60 seconds at an intensity that will cause the tissue to contract 80% of its maximum capacity. All responses are recorded isometrically by means of a Grass force

25

- 26 -

displacement transducer (FT03) and Harvard electronic recorder. Substance P potentiates the electrical field stimulated-induced contractions of the guinea pig vas deferens. In unpaired studies, all tissues (control or drug treated) are exposed to cumulative concentrations of Substance P (1×10^{-10} M - 7×10^{-7} M). Single log-concentrations of the test compounds are given to separate tissues and allowed to equilibrate for 30 minutes before a Substance P concentration-response curve is generated. At least 5 separate tissues are used for each control and individual drug-concentration for every drug assay.

- 5
- 10 Inhibition of the Substance P is demonstrated by a rightward shift of its concentration-response curve. These shifts are used to determine the pA_2 value, which is defined as the negative log of the molar concentration of the inhibitor which would require that twice as much agonist be used to elicit a chosen response. This value is used to
- 15 determine relative antagonist potency.

Isolated Hamster Trachea NK₂ Assay

- General methodology and characterization of hamster trachea responses to neurokinin agonists as providing an NK₂ monoreceptor assay is found in C.A. Maggi, et al., *Eur. J. Pharmacol.* 166 (1989) 435 and J.L. Ellis, et al., *J. Pharm. Exp. Ther.* 267 (1993) 95.
- 20

Continuous isometric tension monitoring is achieved with Grass FT-03 force displacement transducers connected to Buxco Electronics preamplifiers built into a Graphtec Linearcorder Model WR 3310.

- 25 Male Charles River LAK:LVG (SYR) hamsters, 100-200 g fed weight, are stunned by a sharp blow to the head, loss of corneal reflex is assured, the hamsters are sacrificed by thoractomy and cutting the heart. Cervical trachea segments are removed to room temperature Krebs buffer, pH 7.4, aerated with 95% O₂ - 5% CO₂ gas and cleaned of adhering
- 30 tissue. The segments are cut into two 3-4 mm long ring segments. Tracheal rings are suspended from transducers and anchored in 15.0 ml water jacketed organ baths by means of stainless steel hooks and 6-0 silk. Baths are filled with Krebs buffer, pH 7.4, maintained at 37°C and continuously aerated with 95% O₂ - 5% CO₂ gas. Tracheal rings are
- 35 placed under 1.0 g initial tension and allowed a 90 min equilibration period with four 1 μ M NKA challenge, wash and recovery cycles at 20 min intervals. 30 min vehicle pretreatment is followed by cumulative additions

- 27 -

of rising doses of NKA (3 nM - 1 μ M final concentration, 5 min intervals between additions). The final NKA response is followed by a 15 min wash and recovery period. 30 min pretreatment with a test compound or its vehicle is followed by cumulative additions of rising doses of NKA (3 nM - 10 μ M final concentration if necessary, 5 min intervals between additions). The final NKA response is followed by a 1 mM carbachol challenge to obtain a maximal tension response in each tissue.

Tissue responses to NKA are recorded as positive pen displacements over baseline and converted to grams tension by comparison to standard weights. Responses are normalized as a % of the maximal tissue tension. ED₅₀'s are calculated for NKA from the control and treated NKA dose responses and compared. Test compounds resulting in an agonist dose ratio ≥ 2 at a screening concentration of 1 μ M (i.e. $pA_2 \geq 6.0$) are considered actives. Further dose response data is obtained for actives so that an apparent pA_2 estimate can be calculated. pA_2 is calculated either by estimation of K_i as described by Furchgott (where $pA_2 = -\text{Log } K_i$, R.F. Furchgott, *Pharm. Rev.* 7 [1995] 183) or by Shild Plot Analysis (O. Arunlakshana & H.O. Shild, *Br. J. Pharmacol.* 14[1959] 48) if the data is sufficient.

Effect of NK₁ Antagonists on Substance P-Induced Airway Microvascular Leakage in Guinea Pigs

Studies are performed on male Hartley guinea pigs ranging in weight from 400-650 g. The animals are given food and water *ad libitum*. The animals are anesthetized by intraperitoneal injection of dialurethane (containing 0.1 g/ml diallylbarbituric acid, 0.4 g/ml ethylurea and 0.4 g/ml urethane). The trachea is cannulated just below the larynx and the animals are ventilated ($V_T = 4$ ml, $f = 45$ breaths/min) with a Harvard rodent respirator. The jugular vein is cannulated for the injection of drugs.

The Evans blue dye technique (Danko, G. et al., *Pharmacol. Commun.*, 1, 203-209, 1992) is used to measure airway microvascular leakage (AML). Evans blue (30 mg/kg) is injected intravenously, followed 1 min later by i.v. injection of substance P (10 μ g/kg). Five min later, the thorax is opened and a blunt-ended 13-gauge needle passed into the aorta. An incision is made in the right atrium and blood is expelled by flushing 100 ml of saline through the aortic catheter. The lungs and trachea are removed en-bloc and the trachea and bronchi are then blotted

- 28 -

dry with filter paper and weighed. Evans blue is extracted by incubation of the tissue at 37°C for 18 hr in 2 ml of formamide in stoppered tubes. The absorbance of the formamide extracts of dye is measured at 620 nm. The amount of dye is calculated by interpolation from a standard curve of

- 5 Evans blue in the range 0.5-10 µg/ml in formamide. The dye concentration is expressed as ng dye per mg tissue wet weight. Test compounds were suspended in cyclodextran vehicle and given i.v. 5 min before substance P.

Measurement of NK₂ Activity In Vivo

- 10 Male Hartley guinea pigs (400-500 gm) with ad lib. access to food and water are anesthetized with an intraperitoneal injection of 0.9 ml/kg dialurethane (containing 0.1 g/m diallylbarbituric acid, 0.4 g/ml ethylurea and 0.4 g/ml urethane). After induction of a surgical plane of anesthesia, tracheal, esophageal and jugular venous cannulae are
- 15 implanted to facilitate mechanical respiration, measurement of esophageal pressure and administration of drugs, respectively.

- The guinea pigs are placed inside a whole body plethysmograph and the catheters connected to outlet ports in the plethysmograph wall. Airflow is measured using a differential pressure transducer (Validyne, Northridge CA, model MP45-1, range ± 2 cmH₂O) which measures the pressure across a wire mesh screen that covers a 1 inch hole in the wall of the plethysmograph. The airflow signal is electrically integrated to a signal proportional to volume. Transpulmonary pressure is measured as the pressure difference between the trachea and
- 20 the esophagus using a differential pressure transducer (Validyne, Northridge, CA, model MP45-1, range ± 20 cm H₂O). The volume, airflow and transpulmonary pressure signals are monitored by means of a pulmonary analysis computer (Buxco Electronics, Sharon, CT, model 6) and used for the derivation of pulmonary resistance (R_L) and dynamic
- 25 lung compliance (C_{Dyn}).
- 30

Bronchoconstriction Due to NKA

- Increasing iv doses of NKA are administered at half log (0.01-3 µg/kg) intervals allowing recovery to baseline pulmonary mechanics between each dose. Peak bronchoconstriction occurs within
- 35 30 seconds after each dose of agonist. The dose response is stopped when C_{Dyn} is reduced 80-90% from baseline. One dose-response to NKA is performed in each animal. Test compounds are suspended in

- 29 -

cyclodextran vehicle and given i.v. 5 min before the initiation of the NKA dose response.

For each animal, dose response curves to NKA are constructed by plotting the percent increase in R_L or decrease in C_{Dyn} against log dose of agonist. The doses of NKA that increased R_L by 100% (R_L100) or decreased C_{Dyn} by 40% ($C_{Dyn}40$) from baseline values are obtained by log-linear interpolation of the dose response curves.

Neurokinin Receptor Binding Assay(s)

Chinese Hamster ovary (CHO) cells transfected with the coding regions for the human neurokinin 1 (NK1) of the human neurokinin 2 (NK2) receptors are grown in Dulbecco's minimal essential medium supplemented with 10% fetal calf serum, 0.1 mM non-essential amino acids, 2 mM glutamine, 100units/ml of penicillin and streptomycin, and 0.8 mg of G418/ml at 37°C in a humidified atmosphere containing 5% CO₂.

Cells are detached from T-175 flasks with a sterile solution containing 5mM EDTA in phosphate buffered saline. Cells are harvested by centrifugation and washed in RPMI media at 40°C for 5 minutes. The pellet is resuspended in Tris-HCl (pH7.4) containing 1 uM phosphoramidon and 4 ug/ml of chymostatin at a cell density of 30×10^6 cells/ml. The suspension is then homogenized in a Brinkman Polytron (setting 5) for 30-45 seconds. The homogenate is centrifuged at 800 x g for 5 min at 4°C to collect unbroken cells and nuclei. The supernatant is centrifuged in a Sorvall RC5C at 19,000 rpm (44,00 x g) for 30 min at 4°C. The pellet is resuspended, an aliquot is removed for a protein determination (BCA) and washed again. The resulting pellet is stored at -80°C.

To assay receptor binding, 50 µl of [³H]-Substance P (9-Sar, 11-Met [02]) (specific activity 41 Ci/mmol) (Dupont-NEN) (0.8 nM for the NK-1 assay) or [³H]-Neurokinin A (specific activity 114 Ci/ mmole) (Zenca) (1.0 nM for the NK-2 assay) is added to tubes containing buffer (50 mM Tris-HCl (pH 7.4) with 1 mM MnCl₂ and 0.2% Bovine Serum Albumin) and either DMSO or test compound. Binding is initiated by the addition of 100µl of membrane (10-20 µg) containing the human NK-1 or NK-2 receptor in a final volume of 200 µl. After 40 minutes at room temperature, the reaction is stopped by rapid filtration onto Whatman GF/C filters which have been presoaked in 0.3% polyethylenimine. Filters are washed 2 times with 3 ml of 50 mM Tris-HCl (pH7.4). Filters are added to 6 mls of Ready-Safe liquid scintillation cocktail and quantified by liquid scintillation

- 30 -

spectrometry in a LKB 1219 RackBeta counter. Non-specific binding is determined by the addition of either 1 μ M of CP-99994 (NK-1) or 1 μ M SR-48968 (NK-2) (both synthesized by the chemistry department of Schering-Plough Research Institute). IC₅₀ values are determined from competition
5 binding curves and Ki values are determined according to Cheng and Prusoff using the experimentally determined value of 0.8 nM for the NK-1 receptor and 2.4 nM for the NK-2 receptor.

% Inhibition is the difference between the percent of maximum specific binding (MSB) and 100%. The percent of MSB is
10 defined by the following equation, wherein "dpm" is disintegrations per minute:


$$\% \text{ MSB} = \frac{(\text{dpm of unknown}) - (\text{dpm of nonspecific binding})}{(\text{dpm of total binding}) - (\text{dpm of nonspecific binding})} \times 100$$

It will be recognized that compounds of formula I exhibit NK₁, NK₂ and/or NK₃ antagonist activity to varying degrees, e.g., certain
15 compounds have strong NK₁ antagonist activity, but weaker NK₂ and NK₃ antagonist activity, while others are strong NK₂ antagonists, but weaker NK₁ and NK₃ antagonists. While compounds with approximate equipotency are preferred, it is also within the scope of this invention to use compounds of with unequal NK₁/NK₂/NK₃ antagonist activity when
20 clinically appropriate.

Using the test procedures described above, compounds of the present invention exhibit a range of activity: percent inhibition at a dosage of 1 μ M ranges from about 1 to about 81% inhibition of NK₁ and/or about 1 to about 96% inhibition of NK₂. Preferred are compounds
25 exhibiting greater than about 50% inhibition of NK₁ and about 1 to about 96% inhibition of NK₂; also preferred are compounds exhibiting about 1 to about 81% inhibition of NK₁ and greater than about 50% inhibition of NK₂. Also preferred are compounds exhibiting greater than about 50 % inhibition of NK₁ and greater than about 50% inhibition of NK₂; of those
30 compounds, more preferred are compounds exhibiting greater than about 75% inhibition of NK₁ and greater then about 75% inhibition of NK₂.

We claim:

1. A compound represented by the structural formula



- 5 or a pharmaceutically acceptable salt thereof, wherein:
- A¹ is -CH₂R⁶, -OR⁶, -N(R⁶)(R⁷), -S(O)_eR¹³, -(C(R⁶)(R⁷))₁₋₆-OR⁶, -(C(R⁶)(R⁷))₁₋₆-N(R⁶)(R⁷) or -(C(R⁶)(R⁷))₁₋₆-S(O)_eR¹³ and A² is H, or A¹ and A² together are =O, =C(R⁶)(R⁷), =NOR⁶ or =S;
- Q is R⁵-phenyl, R⁵-naphthyl, -SR⁶, -N(R⁶)(R⁷), -OR⁶ or
- 10 R⁵-heteroaryl;
- T is H, R⁴-aryl, R⁴-heterocycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl or R¹⁰-bridged cycloalkyl;
- b is 0, 1 or 2;
- b₁ is 1 or 2;
- 15 X is a bond, -C(O)-, -O-, -NR⁶-, -S(O)_e-, -N(R⁶)C(O)-, -C(O)N(R⁶)-, -OC(O)NR⁶-, -OC(=S)NR⁶-, -N(R⁶)C(=S)O-, -C(=NOR⁶)-, -S(O)₂N(R⁶)-, -N(R⁶)S(O)₂-, -N(R⁶)C(O)O- or -OC(O)-;
- R⁴ and R⁵ are independently 1-3 substituents independently selected from the group consisting of H, halogeno, -OR⁶, -OC(O)R⁶,
- 20 -OC(O)N(R⁶)(R⁷), -N(R⁶)(R⁷), C₁₋₆ alkyl, -CF₃, -C₂F₅, -COR⁶, -CO₂R⁶, -CON(R⁶)(R⁷), -S(O)_eR¹³, -CN, -OCF₃, -NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), R¹⁵-phenyl, R¹⁵-benzyl, NO₂, -N(R⁶)S(O)₂R¹³ or -S(O)₂N(R⁶)(R⁷); or adjacent R⁴ substituents or adjacent R⁵ substituents can form a -O-CH₂-O- group; and R⁴ can also be R¹⁵-heteroaryl;
- 25 R⁶, R⁷, R⁸, R^{8a}, and R¹³ are independently selected from the group consisting of H, C₁₋₆ alkyl, C₂-C₆ hydroxyalkyl, C₁-C₆ alkoxy-C₁-C₆ alkyl, R¹⁵-phenyl, and R¹⁵-benzyl; or R⁶ and R⁷, together with the nitrogen to which they are attached, form a ring of 5 to 6 members, wherein 0, 1 or 2 ring members are selected from the group consisting of
- 30 -O-, -S- and -N(R¹⁹)-;
- R⁹ and R^{9a} are independently selected from the group consisting of R⁶ and -OR⁶, provided that when R⁹ is OH, X is a bond, -C(O)-, -N(R⁶)C(O)- or -C(=NOR⁶)-;

- 32 -

R¹⁰ is independently selected from the group consisting of H and C₁₋₆ alkyl;

R¹⁵ is 1 to 3 substituents independently selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio, halogeno,
 5 -CF₃, -C₂F₅, -COR¹⁰, -CO₂R¹⁰, -C(O)N(R¹⁰)₂, -S(O)_eR¹⁰, -CN,
 -N(R¹⁰)COR¹⁰, -N(R¹⁰)CON(R¹⁰)₂ and -NO₂;


R¹⁶ is C₁₋₆ alkyl, R¹⁵-phenyl or R¹⁵-benzyl;

R¹⁹ is H, C₁₋₆ alkyl, -C(O)N(R¹⁰)₂, -CO₂R¹⁰, -(C(R⁸)(R⁹))_f-
 CO₂R¹⁰ or -(C(R⁸)(R⁹))_u-C(O)N(R¹⁰)₂;

10 f is 1-6;

u is 0-6;

Z is



f is 1-6;

15 g and j are independently 0-3;

h and k are independently 1-4, provided the sum of h and g is 1-7;

J is two hydrogen atoms, =O, =S, =NR⁹ or =NOR⁶;

L and L¹ are independently selected from the group consisting of H,
 C₁₋₆ alkyl, C₁₋₆ alkenyl, -CH₂-cycloalkyl, R¹⁵-benzyl, R¹⁵-heteroaryl,
 20 -C(O)R⁶, -(CH₂)_m-OR⁶, -(CH₂)_m-N(R⁶)(R⁷), -(CH₂)_m-C(O)-OR⁶ and
 -(CH₂)_m-C(O)N(R⁶)(R⁷);

m is 0 to 4, provided that when j is 0, m is 1-4;

R²⁵ is H, C₁₋₆ alkyl, -CN, R¹⁵-phenyl or R¹⁵-benzyl;

R²⁶ and R²⁷ are independently selected from the group consisting
 25 of H, C₁₋₆ alkyl, R⁴-aryl and R⁴-heteroaryl; or R²⁶ is H, C₁₋₆ alkyl, R⁴-
 aryl or R⁴-heteroaryl, and R²⁷ is -C(O)R⁶, -C(O)-N(R⁶)(R⁷), -C(O)(R⁴-aryl),
 -C(O)(R⁴-heteroaryl), -SO₂R¹³ or -SO₂-(R⁴-aryl);

R²⁸ is H, -(C(R⁶)(R¹⁹))_t-G or -(C(R⁶)(R⁷))_v-G²;

t and v are 0, 1, 2 or 3, provided that when j is 0, t is 1, 2 or 3;

30 R²⁹ is H, C₁₋₆ alkyl, -C(R¹⁰)₂S(O)_eR⁶, R⁴-phenyl or R⁴-heteroaryl;

G is H, R⁴-aryl, R⁴-hetero-cycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl,
 -OR⁶, -N(R⁶)(R⁷), -COR⁶, -CO₂R⁶, -CON(R⁷)(R⁹), -S(O)_eR¹³,
 -NR⁶CO₂R¹⁶, -NR⁶COR⁷, -NR⁸CON(R⁶)(R⁷), -N(R⁶)S(O)₂R¹³,
 -S(O)₂N(R⁶)(R⁷), -OC(O)R⁶, -OC(O)N(R⁶)(R⁷), -C(=NOR⁸)N(R⁶)(R⁷),
 35 -C(=NR²⁵)N(R⁶)(R⁷), -N(R⁸)C(=NR²⁵)N(R⁶)(R⁷), -CN, -C(O)N(R⁶)OR⁷ or

- 33 -

-C(O)N(R⁹)-(R⁴-heteroaryl), provided that when n is 1 and u is 0, or when R⁹ is -OR⁶, G is not -OH or -N(R⁶)(R⁷); and


G² is R⁴-aryl, R⁴-heterocycloalkyl, R⁴-heteroaryl, R⁴-cycloalkyl, -COR⁶, -CO₂R¹⁶, -S(O)₂N(R⁶)(R⁷) or -CON(R⁶)(R⁷).

5

2. A compound of claim 1 wherein X is -O-, -NR⁶-, -N(R⁶)C(O)-, -OC(O)NR⁶- or -N(R⁶)C(O)O-.

3. A compound of any of claims 1 or 2 wherein A¹ is -OR⁶, -N(R⁶)(R⁷), -S(O)₂R¹³ or -(C(R⁶)(R⁷))₁₋₆-N(R⁶)(R⁷) and A² is H; or A¹ and A² together are =O, =C(R⁶)(R⁷) or =NOR⁶.

4. A compound of any of claims 1, 2 or 3 wherein T is R⁴-aryl or R⁴-heteroaryl; Q is R⁵ phenyl, R⁵-naphthyl or R⁵-heteroaryl; and Z is selected from the group consisting of:



5. A compound of any of claims 1, 2, 3 or 4 wherein b is 0 or 1; b₁ is 1; X is -NR⁶- or -N(R⁶)C(O)-; R^{8a} and R^{9a} are independently selected from the group consisting of hydrogen, hydroxyalkyl and alkoxyalkyl; T is phenyl substituted by two substituents selected from the group consisting of C₁-C₆ alkyl, halogeno, -CF₃ and C₁-C₆ alkoxy; and Q is phenyl di-substituted by halogeno, naphthyl or benzothienyl.

25

6. A compound of claim 1 which is

N-[2-(3,4-dichlorophenyl)-3-hydroxy-4-(4-hydroxy-4-phenyl-1-piperidiny)butyl]-*N*-methyl benzamide;

- 34 -

N-[3-hydroxy-4-(4-hydroxy-4-phenyl-1-piperidiny)-2-(4-methoxyphenyl)butyl]-*N*-methyl benzamide;

N-[3-hydroxy-4-(4-hydroxy-4-phenyl-1-piperidiny)-2-phenylbutyl]-*N*-methyl benzamide;

5 *N*-[2-(4-chlorophenyl)-3-hydroxy-4-(4-hydroxy-4-phenyl-1-piperidiny)butyl]-*N*-methyl benzamide;

N-[3-hydroxy-4-(4-hydroxy-4-phenyl-1-piperidiny)-2-(4-methylphenyl)butyl]-*N*-methyl benzamide;

10 1,1-dimethylethyl-[2-(3,4-dichlorophenyl)-3-hydroxy-4-(4-hydroxy-4-phenyl-1-piperidiny)butyl]carbamate;

1,1-dimethylethyl-[2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-phenyl-1-piperidiny)-3-methoxybutyl]carbamate;

N-[2-(4-chlorophenyl)-4-(4-hydroxy-4-phenyl-1-piperidiny)-3-methoxybutyl]-*N*-methyl benzamide;

15 *N*-[2-(3,4-dichlorophenyl)-4-(4-methoxy-4-phenyl-1-piperidiny)-3-methoxybutyl]-*N*-methyl benzamide;

N-[2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-phenyl-1-piperidiny)-3-oxobutyl]-*N*-methylbenzamide;

20 *N*-[2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-phenyl-1-piperidiny)-3-(methoxyimino)butyl]-*N*-methylbenzamide; or

N-[3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-(3,4-dichlorophenyl)-4-(4-hydroxy-4-phenyl-1-piperidiny)butyl]-*N*-methyl benzamide;

N-[3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-4-(4-hydroxy-4-phenyl-1-piperidiny)-2-phenylbutyl]-*N*-methylbenzamide;

25 α -[1-(3,4-dichlorophenyl)-2-[methyl(phenylmethyl)amino]ethyl]-4-hydroxy-4-phenyl-1-piperidineethanol; or

1-[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-(3,4-dichlorophenyl)-4-[methyl(phenylmethyl)amino]butyl]-4-phenyl-4-piperidinol.

30

7. A pharmaceutical composition comprising an effective amount of a compound of any of claims 1, 2, 3, 4, 5 or 6 in a pharmaceutically acceptable carrier.

35 8. A method of preparing a composition of claim 7 comprising admixing a compound of any of claims 1 to 6 with pharmaceutically acceptable carrier.

- 35 -

9. The use of a compound of any of claims 1 to 6 for the preparation of a medicament for the treatment of asthma, cough, bronchospasm, central nervous system diseases, inflammatory diseases and gastrointestinal disorders.

10. A method of treating asthma, cough, bronchospasm, central nervous system diseases, inflammatory diseases and gastrointestinal disorders comprising administering an effective amount of a compound of any of claims 1 to 6 to a mammal in need of such treatment.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/16822

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/52 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 474 561 A (SANOFI SA) 11 March 1992 see the whole document & US 5 350 852 A cited in the application ---	1-10
X	WO 94 29309 A (MERCK & CO INC ;MACCOSS MALCOLM (US); MILLS SANDER G (US); SHAH SH) 22 December 1994 cited in the application see the whole document -----	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

17 June 1997

Date of mailing of the international search report

27.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 96/ 16822

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 10 is directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the compounds or compositions.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
Claims searched completely: 5, 6
Claims searched incompletely: 1-4, 7-10

see next sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 96/ 16822

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

The subject matter of the present application is so broad that a complete search is not possible on economic grounds (see Guidelines for Examination in the EPO, Part B, Chapter III, 2). Therefore the search has been based on the examples and the claims as indicated (see Rule 45 EPC).

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Application No

PCT/US 96/16822

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0474561 A	11-03-92	FR 2666335 A	06-03-92
		FR 2678267 A	31-12-92
		AU 657272 B	09-03-95
		AU 8354291 A	12-03-92
		CA 2050639 A	06-03-92
		CS 9102724 A	18-03-92
		FI 98457 B	14-03-97
		HU 9500521 A	30-10-95
		IL 99320 A	31-07-95
		JP 4261155 A	17-09-92
		LT 585 A,B	27-12-94
		LV 10606 B	20-04-96
		NO 177226 B	02-05-95
		NZ 239661 A	27-06-94
		PL 167994 B	30-12-95
		RU 2070196 C	10-12-96
		US 5350852 A	27-09-94
		US 5236921 A	17-08-93
WO 9429309 A	22-12-94	AU 7201194 A	03-01-95
		CA 2163995 A	22-12-94
		EP 0702681 A	27-03-96
		HR 940337 A	30-04-97
		JP 8511522 T	03-12-96
		ZA 9403946 A	20-01-95